Re: "Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research" by Strawn JR and Croarkin PE (J Child Adolesc Psychopharmacol 2018;28:(5)363)

J Child Adolesc Psychopharmacol. 2019 Apr;29(3):245-246. doi: 10.1089/cap.2018.0163. Epub 2019 Mar 15.

Authors

Karen L Weihs¹, Dalia B Wajsbrot², Deborah Chiles³, Sara Ramaker³, Phil Chappell⁴

Affiliations

¹ 1 Department of Psychiatry, University of Arizona, Tucson, Arizona.
² 2 Pfizer, Inc., New York, New York.
³ 3 Pfizer, Inc, Collegeville, Pennsylvania.
⁴ 4 Pfizer, Inc., Groton, Connecticut.

PMID: 30874454
DOI: 10.1089/cap.2018.0163

No abstract available

Publication types

Comment

MeSH terms

Adolescent
Antidepressive Agents
Child
Depressive Disorder, Major*
Desvenlafaxine Succinate
Fluoxetine
Humans
Psychopharmacology*

Substances

Antidepressive Agents
Fluoxetine
Desvenlafaxine Succinate